AneurysmsSTERLINGNCT03642639
A Study to Look at Performance of MICRUSFRAME and GALAXY Coils for the Treatment of Intracranial Aneurysms
A study testing MICRUSFRAME and GALAXY coils in people with Aneurysms, run by Cerenovus, Part of DePuy Synthes Products, Inc. at 51 sites in 10 countries.
Trial summary
A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils Read more about this study
- Who is it for?
- Ages 21 to 80 years
- Conditions the study is for
- Aneurysms
- What is being tested?
- MICRUSFRAME and GALAXY coils
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 723 participants
- Where
- 51 sitesin 10 countries
- Study dates
- 23 Aug 2018to 12 Jun 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is between 21 and 80 years of age
- Patient has an intracranial saccular aneurysm, ruptured or unruptured, suitable for embolization with coils
- Patient is able and willing to comply with protocol and follow-up requirements
Who cannot join
- Pre-planned staged procedure on unruptured aneurysm
- More than one aneurysm requiring treatment during the course of study
- Fusiform aneurysm
Trial locations and contacts
51 sites in 10 countries.
51 sites in 10 countries
United States30 sites
University of Buffalo
Buffalo, New York, 14075
Mercy San Juan Medical Center
Carmichael, California, 95608
Medical University of South Carolina
Charleston, South Carolina, 29425
University of Virginia
Charlottesville, Virginia, 22908
Tennessee Interventional and Imaging Associates
Chattanooga, Tennessee, 37403
Rush University
Chicago, Illinois, 60612
University of Illinois
Chicago, Illinois, 60612
Geisinger Clinic
Danville, Pennsylvania, 17822
Duke University Medical Center
Durham, North Carolina, 27710
University of Florida
Gainesville, Florida, 32608
Greenville Health System
Greenville, South Carolina, 61103
Baptist Medical Center
Jacksonville, Florida, 32207
University of Tennessee
Knoxville, Tennessee, 37920
Norton Healthcare
Louisville, Kentucky, 40241
University of Miami
Miami, Florida, 33136
Mount Sinai Hospital
New York, New York, 10029
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
University of California Irvine
Orange, California, 92868
Texas Stroke Institute
Plano, Texas, 75075
Oregon Health and Science University
Portland, Oregon, 97239
Javon Bea Hospital
Rockford, Illinois, 61103
University of Utah
Salt Lake City, Utah, 84132
Memorial Health University
Savannah, Georgia, 31405
Maine Medical Center
Scarborough, Maine, 04074
St. Louis University
St Louis, Missouri, 63110
Stony Brook University
Stony Brook, New York, 11794
Mercy Health St. Vincent Medical Center
Toledo, Ohio, 43604
University of Arizona
Tucson, Arizona, 85724
Westchester Medical Center
Valhalla, New York, 10595
University of Massachusetts
Worcester, Massachusetts, 01655
Japan6 sites
Aichi Medical University Hospital
Aichi
Okayama University Hospital
Okayama
National Hospital Organization Osaka National Hospital
Osaka
Tominaga Hospital
Osaka
Kohnan Hospital
Sendai
Meihokai Yokohama Shin-Toshi Brain Orthopedic Hospital
Yokohama
France5 sites
Centre Hospitalier Universitaire d'Amiens Picardie
Amiens
Centre Hospitalier Universitaire de Bordeaux
Bordeaux
Hopital Roger Salengro-Centre Hospitalier Universitaire de Lille
Lille
Praticien Hospitalier Université de Lorraine
Nancy
Centre Hospitalier Regional Universitaire de Tours
Tours
Italy3 sites
Ospedale Niguarda Ca' Granda
Milan
Policlinico Tor Vergata
Roma
Ospedale Cannizzaro
Sicily
Switzerland2 sites
Hopitaux Universitaires de Geneve
Geneva
University Hospital Zurich
Zurich
About this study
Official title: A Prospective, Multi-center, Single Arm Study to Obtain "Real World" Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils Including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms
A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils
Read the detailed description
A registry to collect real world data on the use of Cerenovus coils. The study will be a post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils
- Conditions
- Aneurysms
- Being tested
- MICRUSFRAME and GALAXY coils
- Medical subject headings
- Aneurysm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MICRUSFRAME and GALAXY coilsDevice
MICRUSFRAME and GALAXY Coils
| Study group | Role | What they receive |
|---|---|---|
| Coils | Other | MICRUSFRAME and GALAXY coils Receives: Device: MICRUSFRAME and GALAXY coils |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Who Achieved Adequate Occlusion (Modified Raymond-Roy I or II Classification) as Assessed by the Independent Core Lab Report of the Target Aneurysm at 1 Year Without Retreatment
Number of participants who achieved adequate occlusion as assessed by the independent core lab report of the target aneurysm at 1 year without retreatment was reported. Adequate occlusion was defined as the achievement of a Modified Raymond-Roy classification of the aneurysm at 1 year without retreatment. Modified Raymond-Roy Classification scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.
Measured: At 1 year Post Procedure on Day 1
Secondary outcomes (6)
Packing Density Percentage (%) as Assessed by Independent Core Lab
Packing density was defined as the ratio of the volume of coils to the volume of the coiled part of the aneurysm achieved during the procedure. Packing density is expressed as percentage.
Measured: During procedure (Day 1)
Number of Participants With Complete Occlusion at 1 Year as Assessed by the Independent Core Lab (Modified Raymond-Roy I Classification)
Number of participants with complete occlusion at 1 year was reported as assessed by the independent core lab was reported. Complete occlusion was defined as achieving Modified Raymond-Roy I classification at 1 year, as assessed by the independent core lab. Modified Raymond-Roy I or II Classification scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.
Measured: At 1 year Post Procedure on Day 1
Recanalization Rate at 1 Year as Assessed by Independent Core Lab
Recanalization rate is defined as number of participants with recanalization. Recanalization was defined as a worsening in aneurysm occlusion grading using the Modified Raymond-Roy Classification (MRRC) scale. MRRC scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.
Measured: At 1 year Post Procedure on Day 1
Number of Participants With Modified Rankin Score (mRS) 0-2 With Unruptured Aneurysms
Number of participants with mRS 0-2 with unruptured aneurysm was reported. The Modified Rankin Scale (mRS) is a 7 point measure of functional outcome ranging from 0 to 6, where higher scores indicate greater disability. A score of 0 reflects no symptoms, 1 denotes no significant disability despite minor symptoms, 2 indicates slight disability with independence in personal affairs, 3 corresponds to moderate disability requiring some help but able to walk unassisted, 4 represents moderately severe disability with dependence for bodily needs and inability to walk alone, 5 signifies severe disability requiring constant care, and 6 indicates death. Increasing scores indicate worsening outcomes.
Measured: From baseline (Day 1 of procedure) to 1 year post procedure on Day 1
Number of Participants With Retreatment (Surgical or Endovascular)
Number of participants with any retreatment (surgical or endovascular) was reported. Retreatment is defined as any type of additional treatment (surgical or endovascular) of the target aneurysm after the index procedure.
Measured: From baseline (Day 1 of procedure) to 1 year post procedure on Day 1
Number of Participants With Device Related Serious Adverse Events (SAEs)
An adverse event (AE) is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, users or other persons, whether or not related to the investigational medical device and whether anticipated or unanticipated. A serious adverse event (SAE) is defined as an adverse event that led to death, led to serious deterioration in the health of the participant, users, other persons as defined by one or more of the following: a life-threatening illness or injury, or a permanent impairment of a body structure or a body function including chronic diseases, or in-patient or prolonged hospitalization, or medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function led to fetal distress, fetal death or a congenital abnormality or birth defect including physical or mental impairment.
Measured: From Day of procedure (Day 1) up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2018
- Study start23 Aug 2018
- Primary completion12 Jun 2025
- Study completion12 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for AneurysmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 723 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Reade De Leacy, Principal investigator, Mount Sinai Hospital, New YorkOsama Zaidat, Principal investigator, Mercy Health St. Vincent Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03642639
- Sponsor's protocol ID
- CNV_2017_01
- Acronym
- STERLING
- Status last verified
- Jun 2026
- First submitted
- 11 Jul 2018
- Last updated
- 9 Jul 2026
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multi-center, Single Arm Study to Obtain "Real World" Clinical Data and Characterize the Acute and Long-term Performance of the MICRUSFRAME and GALAXY Coils Including the PulseRider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms
- ClinicalTrials.gov ID
- NCT03642639
- Acronym / sponsor ID
- STERLING / CNV_2017_01
- Conditions
- Aneurysms
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 723 participants (actual)
- Lead sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.Industry (pharma, biotech, devices)
- Study start
- 23 Aug 2018 (actual)
- Primary completion
- 12 Jun 2025 (actual)
- Study completion
- 12 Jun 2025 (actual)
- First posted
- 22 Aug 2018 (actual)
- Results
- Posted 9 Jul 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils
Detailed description
A registry to collect real world data on the use of Cerenovus coils. The study will be a post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Coils | Other | Device: MICRUSFRAME and GALAXY coilsMICRUSFRAME and GALAXY coils |
Who may qualify
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patient is between 21 and 80 years of age
- Patient has an intracranial saccular aneurysm, ruptured or unruptured, suitable for embolization with coils
- Patient is able and willing to comply with protocol and follow-up requirements
Key exclusion criteria (3 listed)
- Pre-planned staged procedure on unruptured aneurysm
- More than one aneurysm requiring treatment during the course of study
- Fusiform aneurysm
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MICRUSFRAME and GALAXY coilsMICRUSFRAME and GALAXY Coils | Device | Coils |
Primary outcome
Number of Participants Who Achieved Adequate Occlusion (Modified Raymond-Roy I or II Classification) as Assessed by the Independent Core Lab Report of the Target Aneurysm at 1 Year Without Retreatment
Time frame: At 1 year Post Procedure on Day 1
Number of participants who achieved adequate occlusion as assessed by the independent core lab report of the target aneurysm at 1 year without retreatment was reported. Adequate occlusion was defined as the achievement of a Modified Raymond-Roy classification of the aneurysm at 1 year without retreatment. Modified Raymond-Roy Classification scale is a system used to grade the angiographic results of endovascular treatment of brain aneurysms. Class I represents complete obliteration of the aneurysm. Class II indicates residual neck, defined as persistence of a portion of the original arterial wall defect without opacification of the aneurysmal wall. Class III is subdivided into IIIa and IIIb: Class IIIa refers to residual aneurysm filling with contrast opacification within the coil interstices, whereas Class IIIb denotes residual aneurysm filling with contrast outlining the aneurysm wall.
6 secondary outcomes
Packing Density Percentage (%) as Assessed by Independent Core Lab
Time frame: During procedure (Day 1)
Number of Participants With Complete Occlusion at 1 Year as Assessed by the Independent Core Lab (Modified Raymond-Roy I Classification)
Time frame: At 1 year Post Procedure on Day 1
Recanalization Rate at 1 Year as Assessed by Independent Core Lab
Time frame: At 1 year Post Procedure on Day 1
Number of Participants With Modified Rankin Score (mRS) 0-2 With Unruptured Aneurysms
Time frame: From baseline (Day 1 of procedure) to 1 year post procedure on Day 1
Number of Participants With Retreatment (Surgical or Endovascular)
Time frame: From baseline (Day 1 of procedure) to 1 year post procedure on Day 1
Number of Participants With Device Related Serious Adverse Events (SAEs)
Time frame: From Day of procedure (Day 1) up to 1 year
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Aneurysms
RecruitingObservational study
A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms
Intracranial Aneurysm
Recruiting
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
RecruitingObservational study
Evaluation of Intestinal Microbiota Implication in Ruptured Intracranial Aneurysm
Intracranial Sacciform Aneurysm
Not yet recruiting
The NUVASCULAR HARBOR Occlusion Device EU Study
Intracranial Arterial Aneurysm
Not yet recruiting
Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling
Intracranial Aneurysm, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Reade De Leacy principal investigator
Mount Sinai Hospital, New York
Osama Zaidat principal investigator
Mercy Health St. Vincent Hospital
51 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MICRUSFRAME and GALAXY coils in people with Aneurysms, run by Cerenovus, Part of DePuy Synthes Products, Inc. at 51 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 51 sites in United States, Japan, France, Italy, Switzerland and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Who Achieved Adequate Occlusion (Modified Raymond-Roy I or II Classification) as Assessed by the Independent Core Lab Report of the Target Aneurysm at 1 Year Without Retreatment (time frame: At 1 year Post Procedure on Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.